Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 6/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.40 |
| ▸ | MEN1 | O00255 | 2/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | ATM | Q13315 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 2/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 2/20 | 0.38 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.38 |
| ▸ | HPGD | P15428 | 2/20 | 0.37 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.37 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.37 |
| ▸ | GAK | O14976 | 3/20 | 0.36 |
| ▸ | RAB9A | P51151 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 2/20 | 0.35 |
| ▸ | GLA | P06280 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1934298 | 1.00 | ALDH1A1 (0.40) | ALDH1A1KDM4EKMT2AMEN1LMNA | |
| SCHEMBL18436330 | 0.81 | L3MBTL1 (0.41) | ALDH1A1KDM4EKMT2AMEN1LMNA | |
| SCHEMBL18436994 | 0.81 | L3MBTL1 (0.41) | ALDH1A1KDM4EKMT2AMEN1LMNA | |
| SCHEMBL18436785 | 0.80 | HRH3 (0.38) | ALDH1A1KDM4EKMT2AMEN1LMNA | |
| SCHEMBL14144924 | 0.80 | KMT2A (0.47) | ALDH1A1KDM4EKMT2AMEN1LMNA | |
| SCHEMBL16603150 | 0.80 | F2RL3 (0.38) | ALDH1A1KDM4EKMT2AMEN1LMNA | |
| SCHEMBL19070105 | 0.80 | F2RL3 (0.38) | ALDH1A1KDM4EKMT2AMEN1LMNA | |
| SCHEMBL20299030 | 0.79 | AR (0.38) | ALDH1A1KDM4EKMT2AMEN1LMNA | |
| SCHEMBL19001040 | 0.78 | LMNA (0.59) | ALDH1A1KDM4EKMT2AMEN1LMNA | |
| SCHEMBL19001122 | 0.78 | LMNA (0.59) | ALDH1A1KDM4EKMT2AMEN1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2504333-B1 | Morpholinothiazoles as alpha 7 positive allosteric modulators | JANSSEN PHARMACEUTICA NV (BE) | 2015-07-15 | — | — | EP | disclosed |
| US-8637510-B2 | Morpholinothiazoles as alpha 7 positive allosteric modulators | JANSSEN PHARMACEUTICA NV (BE) | 2014-01-28 | — | — | US | disclosed |
| EP-2504333-A1 | MORPHOLINOTHIAZOLES AS ALPHA 7 POSITIVE ALLOSTERIC MODULATORS | Janssen Pharmaceutica N.V. (BE) | 2012-10-03 | — | — | EP | disclosed |
| US-20120238561-A1 | MORPHOLINOTHIAZOLES AS ALPHA 7 POSITIVE ALLOSTERIC MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2012-09-20 | — | — | US | disclosed |
| CN-102639530-A | Morpholinothiazoles as alpha 7 positive allosteric modulators | JANSSEN PHARMACEUTICA NV | 2012-08-15 | — | — | CN | disclosed |
| WO-2011064288-A1 | MORPHOLINOTHIAZOLES AS ALPHA 7 POSITIVE ALLOSTERIC MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2011-06-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120238561-A1 | MORPHOLINOTHIAZOLES AS ALPHA 7 POSITIVE ALLOSTERIC MODULATORS | CHRNA7, CHRNE, CHRNA1 | ALDH1A1 3745/4885KDM4E 963/4885KMT2A 1735/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.